187 related articles for article (PubMed ID: 15508132)
1. Selective prescribing of atypical antipsychotics.
Breekveldt-Postma NS; Schillevoort I; Nolen WA; Veraart CP; Herings RM
Pharmacoepidemiol Drug Saf; 2005 Jan; 14(1):25-30. PubMed ID: 15508132
[TBL] [Abstract][Full Text] [Related]
2. Adjunctive use of atypical antipsychotics and anticholinergic drugs among patients with schizophrenia.
Ren XS; Huang YH; Lee AF; Miller DR; Qian S; Kazis L
J Clin Pharm Ther; 2005 Feb; 30(1):65-71. PubMed ID: 15659005
[TBL] [Abstract][Full Text] [Related]
3. Predictors for starting depot administration of risperidone in chronic users of antipsychotics.
Vehof J; Postma MJ; Bruggeman R; De Jong-Van Den Berg LT; Van Den Berg PB; Stolk RP; Burger H
J Clin Psychopharmacol; 2008 Dec; 28(6):625-30. PubMed ID: 19011430
[TBL] [Abstract][Full Text] [Related]
4. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia.
Ascher-Svanum H; Zhu B; Faries D; Landbloom R; Swartz M; Swanson J
BMC Psychiatry; 2006 Feb; 6():8. PubMed ID: 16504026
[TBL] [Abstract][Full Text] [Related]
5. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
István S; Agoston T; Tamás T; Zoltán J
Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
[TBL] [Abstract][Full Text] [Related]
6. [Use of atypical antipsychotics in Charles Perrens psychiatric hospital (Bordeaux) analysis of prescribing practices for Amisulpride, Clozapine, Olanzapine and Risperidone].
Bret P; Bonnet F; Bret MC; Jaffré A
Encephale; 2002; 28(4):329-42. PubMed ID: 12232542
[TBL] [Abstract][Full Text] [Related]
7. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics.
Miller CH; Mohr F; Umbricht D; Woerner M; Fleischhacker WW; Lieberman JA
J Clin Psychiatry; 1998 Feb; 59(2):69-75. PubMed ID: 9501888
[TBL] [Abstract][Full Text] [Related]
8. Antipsychotic-induced extrapyramidal syndromes in psychiatric practice: a case-control study.
Schillevoort I; Herings RM; Hugenholtz GW; de Boer A; Nolen WA; Roos RA; Leufkens HG
Pharm World Sci; 2005 Aug; 27(4):285-9. PubMed ID: 16228625
[TBL] [Abstract][Full Text] [Related]
9. Risk of extrapyramidal syndromes with haloperidol, risperidone, or olanzapine.
Schillevoort I; de Boer A; Herings RM; Roos RA; Jansen PA; Leufkens HG
Ann Pharmacother; 2001 Dec; 35(12):1517-22. PubMed ID: 11793611
[TBL] [Abstract][Full Text] [Related]
10. Antipsychotic-induced extrapyramidal syndromes. Risperidone compared with low- and high-potency conventional antipsychotic drugs.
Schillevoort I; de Boer A; Herings RM; Roos RA; Jansen PA; Leufkens HG
Eur J Clin Pharmacol; 2001 Jul; 57(4):327-31. PubMed ID: 11549212
[TBL] [Abstract][Full Text] [Related]
11. Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials.
Cavazzoni PA; Berg PH; Kryzhanovskaya LA; Briggs SD; Roddy TE; Tohen M; Kane JM
J Clin Psychiatry; 2006 Jan; 67(1):107-13. PubMed ID: 16426096
[TBL] [Abstract][Full Text] [Related]
12. Reduced basal ganglia volumes after switching to olanzapine in chronically treated patients with schizophrenia.
Lang DJ; Kopala LC; Vandorpe RA; Rui Q; Smith GN; Goghari VM; Lapointe JS; Honer WG
Am J Psychiatry; 2004 Oct; 161(10):1829-36. PubMed ID: 15465980
[TBL] [Abstract][Full Text] [Related]
13. The use of atypical antipsychotics in the treatment of schizophrenia in North Staffordshire.
Hodgson R; Belgamwar R; Al-tawarah Y; MacKenzie G
Hum Psychopharmacol; 2005 Mar; 20(2):141-7. PubMed ID: 15651052
[TBL] [Abstract][Full Text] [Related]
14. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.
Kapur S; Zipursky RB; Remington G
Am J Psychiatry; 1999 Feb; 156(2):286-93. PubMed ID: 9989565
[TBL] [Abstract][Full Text] [Related]
15. Comparison of risperidone and olanzapine as used under "real-world" conditions in a state psychiatric hospital.
Advokat C; Dixon D; Schneider J; Comaty JE
Prog Neuropsychopharmacol Biol Psychiatry; 2004 May; 28(3):487-95. PubMed ID: 15093956
[TBL] [Abstract][Full Text] [Related]
16. Atypical antipsychotic use for adult outpatients in New Zealand's Auckland and Northland regions.
Wheeler A
N Z Med J; 2006 Jul; 119(1237):U2055. PubMed ID: 16862201
[TBL] [Abstract][Full Text] [Related]
17. Typical and atypical antipsychotics--the misleading dichotomy. Results from the Working Group 'Drugs in Psychiatry' (AGATE).
Fischer-Barnicol D; Lanquillon S; Haen E; Zofel P; Koch HJ; Dose M; Klein HE;
Neuropsychobiology; 2008; 57(1-2):80-7. PubMed ID: 18515977
[TBL] [Abstract][Full Text] [Related]
18. Increased risk of extrapyramidal side-effect treatment associated with atypical antipsychotic polytherapy.
Carnahan RM; Lund BC; Perry PJ; Chrischilles EA
Acta Psychiatr Scand; 2006 Feb; 113(2):135-41. PubMed ID: 16423165
[TBL] [Abstract][Full Text] [Related]
19. Tolerability of outpatient antipsychotic treatment: 36-month results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study.
Novick D; Haro JM; Perrin E; Suarez D; Texeira JM
Eur Neuropsychopharmacol; 2009 Aug; 19(8):542-50. PubMed ID: 19500949
[TBL] [Abstract][Full Text] [Related]
20. Atypical antipsychotic drugs and diabetes mellitus in a large outpatient population: a retrospective cohort study.
Østbye T; Curtis LH; Masselink LE; Hutchison S; Wright A; Dans PE; Schulman KA; Krishnan RR
Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):407-15. PubMed ID: 15372671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
